The test is covered for serial use in patients with colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period.

The firms will distribute NowDx's First to Know test to more than 15 organizations nationwide, including LGBTQ+ health centers, HIV/AIDS care providers, and safety net clinics.

The acquisition was opposed by some Quanterix shareholders. In May, Akoya also said it received an unsolicited acquisition bid for the firm.